{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:50Z","timestamp":1786979930315,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011087","name":"Society of Interventional Radiology","doi-asserted-by":"publisher","award":["Allied Scientist"],"award-info":[{"award-number":["Allied Scientist"]}],"id":[{"id":"10.13039\/100011087","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Scientist Training Program","award":["T32GM008152"],"award-info":[{"award-number":["T32GM008152"]}]},{"name":"NIH","award":["NIH grant CA126809"],"award-info":[{"award-number":["NIH grant CA126809"]}]},{"name":"NIH","award":["5R25 CA 132822-03"],"award-info":[{"award-number":["5R25 CA 132822-03"]}]},{"name":"NIH","award":["NCI P30-CA060553"],"award-info":[{"award-number":["NCI P30-CA060553"]}]},{"name":"BTG","award":["Investigator Initiated Study"],"award-info":[{"award-number":["Investigator Initiated Study"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00270-020-02538-x","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T13:02:39Z","timestamp":1591966959000},"page":"1528-1537","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Feasibility of Combination Intra-arterial Yttrium-90 and Irinotecan Microspheres in the VX2 Rabbit Model"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0092-249X","authenticated-orcid":false,"given":"Andrew C.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa L.","family":"Gates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Procissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen R.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianchu","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoke","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Dreher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed A.","family":"Omary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"issue":"4","key":"2538_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.6004\/jnccn.2018.0021","volume":"16","author":"AB Benson","year":"2018","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen Y-J, Ciombor KK, et al. NCCN guidelines: colon cancer, Version 42018. J Natl Compr Canc Netw. 2018;16(4):359\u201369.","journal-title":"J Natl Compr Canc Netw."},{"issue":"6","key":"2538_CR2","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","volume":"151","author":"R Salem","year":"2016","unstructured":"Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with\u00a0hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155\u201363.","journal-title":"Gastroenterology"},{"key":"2538_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2013.02.031","author":"S Mouli","year":"2013","unstructured":"Mouli S, Memon K, Baker T, Benson AB, Mulcahy MF, Gupta R, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013. https:\/\/doi.org\/10.1016\/j.jvir.2013.02.031.","journal-title":"J Vasc Interv Radiol"},{"issue":"10","key":"2538_CR4","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.jvir.2014.07.007","volume":"25","author":"AC Gordon","year":"2014","unstructured":"Gordon AC, Gradishar WJ, Kaklamani VG, Thuluvath AJ, Ryu RK, Sato KT, et al. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy. J Vasc Interv Radiol. 2014;25(10):1523\u201332.","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"2538_CR5","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/j.jvir.2013.12.256","volume":"25","author":"AC Gordon","year":"2014","unstructured":"Gordon AC, Ryu R, Sato KT, Gates VL, Salem R, Lewandowski RJ. Yttrium-90 radioembolization for hepatic breast cancer metastasis: a contemporary analysis of safety, response, and survival. J Vasc Interv Radiol. 2014;25(3):S91.","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"2538_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/COC.0b013e31815e4557","volume":"31","author":"AS Kennedy","year":"2008","unstructured":"Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31(3):271\u20139.","journal-title":"Am J Clin Oncol"},{"issue":"02","key":"2538_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1055\/s-0037-1601852","volume":"34","author":"A Gordon","year":"2017","unstructured":"Gordon A, Uddin O, Riaz A, Salem R, Lewandowski R. Making the case: intra-arterial therapy for less common metastases. Semin Intervent Radiol. 2017;34(02):132\u20139.","journal-title":"Semin Intervent Radiol"},{"issue":"2","key":"2538_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1148\/radiol.2472062029","volume":"247","author":"KT Sato","year":"2008","unstructured":"Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres-safety, efficacy, and survival. Radiology. 2008;247(2):507\u201315.","journal-title":"Radiology"},{"issue":"12","key":"2538_CR9","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jvir.2009.08.013","volume":"20","author":"KT Sato","year":"2009","unstructured":"Sato KT, Omary RA, Takehana C, Ibrahim S, Lewandowski RJ, Ryu RK, et al. The role of tumor vascularity in predicting survival after yttrium-90 radioembolization for liver metastases. J Vasc Interv Radiol. 2009;20(12):1564\u20139.","journal-title":"J Vasc Interv Radiol"},{"issue":"9\u201310","key":"2538_CR10","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/sj.bjc.6690233","volume":"79","author":"K Takeda","year":"1999","unstructured":"Takeda K, Negoro S, Kudoh S, Okishio K, Masuda N, Takada M, et al. Phase I\/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. Brit J Cancer. 1999;79(9\u201310):1462\u20137.","journal-title":"Brit J Cancer"},{"issue":"12","key":"2538_CR11","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jvir.2018.08.010","volume":"29","author":"A Fereydooni","year":"2018","unstructured":"Fereydooni A, Letzen B, Ghani MA, Miszczuk MA, Huber S, Chapiro J, et al. Irinotecan-eluting 75-150-\u03bcm embolics lobar chemoembolization in patients with colorectal cancer liver metastases: a prospective single-center phase I study. J Vasc Interv Radiol. 2018;29(12):1646\u201353.","journal-title":"J Vasc Interv Radiol"},{"issue":"7","key":"2538_CR12","first-page":"3413","volume":"36","author":"O Akinwande","year":"2016","unstructured":"Akinwande O, Scoggins C, Martin RCG. Early experience with 70\u2013150\u00a0\u03bcm Irinotecan drug-eluting beads (M1-DEBIRI) for the treatment of unresectable hepatic colorectal metastases. Anticancer Res. 2016;36(7):3413\u20138.","journal-title":"Anticancer Res"},{"issue":"1","key":"2538_CR13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1245\/s10434-010-1288-5","volume":"18","author":"RCG Martin","year":"2011","unstructured":"Martin RCG, Joshi J, Robbins K, Tomalty D, Bosnjakovik P, Derner M, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol. 2011;18(1):192\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"2538_CR14","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1002\/cncr.29534","volume":"121","author":"RCG Martin","year":"2015","unstructured":"Martin RCG, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121(20):3649\u201358.","journal-title":"Cancer"},{"issue":"4","key":"2538_CR15","first-page":"1387","volume":"32","author":"G Fiorentini","year":"2012","unstructured":"Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32(4):1387\u201395.","journal-title":"Anticancer Res"},{"key":"2538_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3389\/fonc.2014.00199","volume":"4","author":"AJAT Braat","year":"2014","unstructured":"Braat AJAT, Huijbregts JE, Molenaar IQ, Borel Rinkes IHM, van den Bosch MAAJ, Lam MGEH. Hepatic radioembolization as a bridge to liver surgery. Front Oncol. 2014;4:199.","journal-title":"Front Oncol."},{"key":"2538_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40336-016-0172-0","volume":"4","author":"MNGJA Braat","year":"2016","unstructured":"Braat MNGJA, Samim M, Van den Bosch MAAJ, Lam MGEH. The role of 90Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review. Clin Transl Imaging. 2016;4:283\u201395.","journal-title":"Clin Transl Imaging"},{"issue":"1","key":"2538_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1477-2574.2009.00117.x","volume":"12","author":"M Bower","year":"2010","unstructured":"Bower M, Metzger T, Robbins K, Tomalty D, V\u00e1lek V, Boudn\u00fd J, et al. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. HPB (Oxford). 2010;12(1):31\u20136.","journal-title":"HPB (Oxford)."},{"issue":"4","key":"2538_CR19","doi-asserted-by":"publisher","first-page":"e0123888","DOI":"10.1371\/journal.pone.0123888","volume":"10","author":"SB White","year":"2015","unstructured":"White SB, Chen J, Gordon AC, Harris KR, Nicolai JR, West DL, et al. Percutaneous ultrasound guided Implantation of VX2 for creation of a rabbit hepatic tumor model. PLoS ONE. 2015;10(4):e0123888.","journal-title":"PLoS ONE"},{"issue":"8","key":"2538_CR20","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1097\/01.RVI.0000233785.75257.9A","volume":"17","author":"R Salem","year":"2006","unstructured":"Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17(8):1251\u201378.","journal-title":"J Vasc Interv Radiol"},{"issue":"15","key":"2538_CR21","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1200\/JCO.2015.66.1181","volume":"34","author":"GA Van Hazel","year":"2016","unstructured":"Van Hazel GA, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Peeters M, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1723\u201331.","journal-title":"J Clin Oncol"},{"key":"2538_CR22","unstructured":"Harpreet SW, Peter G, Navesh KS, Julien T, Volker H, Jens R, Marc P, Michael F, Jamie M, Charles W, Richard A, Anne F, Joanna M, Pradeep SV, Peter D, Sharon L et al., Articles First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license 2017; 18(9):1159\u20131171."},{"issue":"9138","key":"2538_CR23","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","volume":"352","author":"D Cunningham","year":"1998","unstructured":"Cunningham D, Pyrh\u00f6nen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352(9138):1413\u20138.","journal-title":"Lancet"},{"issue":"9138","key":"2538_CR24","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","volume":"352","author":"P Rougier","year":"1998","unstructured":"Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352(9138):1407\u201312.","journal-title":"Lancet"},{"issue":"25","key":"2538_CR25","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1200\/JCO.2008.20.8116","volume":"27","author":"GA Van Hazel","year":"2009","unstructured":"Van Hazel GA, Pavlakis N, Goldstein D, Olver IN, Tapner MJ, Price D, et al. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol. 2009;27(25):4089\u201395.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2538_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejps.2006.09.002","volume":"30","author":"RR Taylor","year":"2007","unstructured":"Taylor RR, Tang Y, Gonzalez MV, Stratford PW, Lewis AL. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci. 2007;30(1):7\u201314.","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"2538_CR27","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1007\/s00270-010-9937-4","volume":"33","author":"RCG Martin","year":"2010","unstructured":"Martin RCG, Howard J, Tomalty D, Robbins K, Padr R, Bosnjakovic PM, et al. Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Inter Rad. 2010;33(5):960\u20136.","journal-title":"Cardiovasc Inter Rad."},{"issue":"6","key":"2538_CR28","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1007\/s00270-012-0343-y","volume":"35","author":"PP Rao","year":"2012","unstructured":"Rao PP, Pascale F, Seck A, Auperin A, Drouard-Troalen L, Deschamps F, et al. Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model. Cardiovasc Inter Rad. 2012;35(6):1448\u201359.","journal-title":"Cardiovasc Inter Rad."},{"issue":"7","key":"2538_CR29","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jvir.2014.04.005","volume":"25","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Nishiofuku H, Hukuoka Y, Sato T, Masada T, Takano M, et al. Pharmacokinetics and antitumor efficacy of chemoembolization using 40\u00a0\u00b5m irinotecan-loaded microspheres in a rabbit liver tumor model. J Vasc Interv Radiol. 2014;25(7):1037\u201344.","journal-title":"J Vasc Interv Radiol"},{"key":"2538_CR30","doi-asserted-by":"crossref","unstructured":"Pasciak AS, Bourgeois AC, Bradley YC. A microdosimetric analysis of tumor absorbed-dose as a function of the number of microspheres per unit volume in Yttrium-90 radioembolization. J Nucl Med. 2016","DOI":"10.2967\/jnumed.115.163444"},{"issue":"4","key":"2538_CR31","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/CAD.0b013e3283425c14","volume":"22","author":"H Illum","year":"2011","unstructured":"Illum H. Irinotecan and radiosensitization in rectal cancer. Anticancer Drugs. 2011;22(4):324\u20139.","journal-title":"Anticancer Drugs"},{"issue":"4","key":"2538_CR32","first-page":"1667","volume":"53","author":"Y Wang","year":"2018","unstructured":"Wang Y, Yang L, Zhang J, Zhou M, Shen L, Deng W, et al. Radiosensitization by irinotecan is attributed to G2\/M phase arrest, followed by enhanced apoptosis, probably through the ATM\/Chk\/Cdc25C\/Cdc2 pathway in p53-mutant colorectal cancer cells. Int J Oncol. 2018;53(4):1667\u201380.","journal-title":"Int J Oncol"},{"issue":"10","key":"2538_CR33","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S1051-0443(07)61299-8","volume":"11","author":"JF Geschwind","year":"2000","unstructured":"Geschwind JF, Artemov D, Abraham S, Omdal D, Huncharek MS, McGee C, et al. Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis. J Vasc Interv Radiol. 2000;11(10):1245\u201355.","journal-title":"J Vasc Interv Radiol"},{"key":"2538_CR34","doi-asserted-by":"crossref","unstructured":"Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, Russell R, et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. 2003. pp. 762\u201377.","DOI":"10.1053\/gast.2003.50094"},{"issue":"1\u20132","key":"2538_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10555-012-9404-6","volume":"32","author":"RL Johnson","year":"2013","unstructured":"Johnson RL, Fleet JC. Animal models of colorectal cancer. Cancer Metastasis Rev. 2013;32(1\u20132):39\u201361.","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"2538_CR36","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1053\/j.gastro.2012.07.110","volume":"143","author":"T Flisikowska","year":"2012","unstructured":"Flisikowska T, Merkl C, Landmann M, Eser S, Rezaei N, Cui X, et al. A porcine model of familial adenomatous polyposis. Gastroenterology. 2012;143(5):1173\u20137.","journal-title":"Gastroenterology"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-020-02538-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-020-02538-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-020-02538-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T19:19:18Z","timestamp":1623439158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-020-02538-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["2538"],"URL":"https:\/\/doi.org\/10.1007\/s00270-020-02538-x","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"17 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"RAO and ACL are founders and owners of IO-RAD and received grant funding from BTG for this study. SBW is a consultant for IO-RAD and Guerbet, and receives research support from Siemens and Guerbet. RJL and RS served as scientific advisors to BTG. RJL is a consultant for ABK. MRD is an employee of BTG. None of the other authors have identified any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}